Falnidamol

Research use only, not for human use.

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. It displays >1000-fold lower potency against ErbB2 (IC50=3.4 μM) and other related tyrosine kinases (IC50>10 μM).

Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity.

Falnidamol (BIBX 1382) demonstrates antiproliferative activity in mitogenic assays performed with KB cells.

Falnidamol (BIBX 1382; p.o.; 10 mg/kg/day; 16 days) completely suppressed tumor growth of human A431 xenografts with respective a T/C value of 15% after 2 weeks of treatment. Falnidamol (50 mg/kg/day for 2 weeks) results in dephosphorylation of the EGF receptor in A431 xenograft-bearing mice. With Falnidamol (p.o.; 10 mg/kg/day; 16 days), the C4h is 2222 nM and the C24h is 244 nM. Animal Model:Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) with A431, FaDu, or HN5 cells Dosage:10 mg/kg Administration:p.o.; daily; 16 days Result:Completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment.Animal Model:Five- to six-week-old athymic NMRI-nu/nu female mice (21–31 g) with A431 cells Dosage:10 mg/kg (Pharmacokinetic Analysis)Administration:p.o.; daily; 16 days Result:The C4h is 2222 nM and the C24h is 244 nM.

——

Angiogenesis

EGFR

EGFR

——

——

196612-93-8

387.84

C18H19ClFN7

>98% (HPLC)

In Vitro:?DMSO : 31.25 mg/mL (80.57 mM; Ultrasonic (<60°C)

CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1

——

(-20℃)

With Ice Pack

≥ 2 years